SFU spin-off company, Alectos Therapeutics announces research partnership with Merck to fight Alzheimer's Disease
Aug 12, 2010
Alectos Therapeutics, Inc., a spin-off biotechnology company from SFU, was co-founded by Dr. David Vocadlo (Alectos CSO and Associate Professor of Chemistry at SFU) and Dr. Ernest McEachern (Alectos CEO).
For more information, please visit Alectos at www.alectos.com .
Dr. David Vocadlo, Alectos CSO
& Associate Professor, Chemistry, SFU
Dr. Ernest McEachern, Alectos CEO